Capricorn Fund Managers Ltd Buys New Stake in Madrigal Pharmaceuticals, Inc. $MDGL

Key Points

• Capricorn Fund Managers bought a new stake of 6,600 shares in Madrigal during Q4, valued at about $3.84 million, and the stock is highly institutionally held at roughly 98.5%.
• Research analysts carry a consensus rating of "Moderate Buy" with an average target of $685.31, and several firms have higher objectives (UBS at $900 among them).
• Madrigal reported a Q4 EPS loss of $-2.57 (vs. $0.04 expected) but revenue of $321.08M, up 210.8% year‑over‑year, while insiders have sold about 55,612 shares (~$28.3M) in the last 90 days and currently own 21.5% of the stock.

Capricorn Fund Managers Ltd bought a new stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 6,600 shares of the biopharmaceutical company's stock, valued at approximately $3,843,000.

Several other hedge funds also recently bought and sold shares of MDGL. Baker BROS. Advisors LP lifted its stake in shares of Madrigal Pharmaceuticals by 8.4% during the third quarter. Baker BROS. Advisors LP now owns 2,141,701 shares of the biopharmaceutical company's stock valued at $982,313,000 after buying an additional 165,683 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH grew its stake in Madrigal Pharmaceuticals by 388.3% in the 3rd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 15,288 shares of the biopharmaceutical company's stock worth $7,012,000 after acquiring an additional 12,157 shares during the period. Iron Triangle Partners LP acquired a new position in Madrigal Pharmaceuticals in the 3rd quarter valued at $26,776,000. Voya Investment Management LLC raised its holdings in Madrigal Pharmaceuticals by 16.3% in the 3rd quarter. Voya Investment Management LLC now owns 59,437 shares of the biopharmaceutical company's stock valued at $27,261,000 after acquiring an additional 8,347 shares during the last quarter. Finally, Calamos Advisors LLC purchased a new position in shares of Madrigal Pharmaceuticals during the 3rd quarter worth $2,057,000. Hedge funds and other institutional investors own 98.50% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have recently commented on MDGL. UBS Group set a $900.00 price objective on Madrigal Pharmaceuticals in a research report on Friday, December 19th. B. Riley Financial increased their target price on Madrigal Pharmaceuticals from $560.00 to $670.00 and gave the stock a "buy" rating in a research report on Thursday, December 11th. Citigroup reissued an "outperform" rating on shares of Madrigal Pharmaceuticals in a research note on Tuesday, January 20th. Zacks Research raised shares of Madrigal Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research note on Friday, February 20th. Finally, The Goldman Sachs Group reiterated a "buy" rating and set a $571.00 price objective on shares of Madrigal Pharmaceuticals in a report on Wednesday, January 14th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $685.31.

Madrigal Pharmaceuticals Stock Performance

Shares of NASDAQ:MDGL opened at $546.89 on Monday. The business has a 50-day moving average of $467.44 and a two-hundred day moving average of $494.01. The firm has a market capitalization of $12.55 billion, a PE ratio of -42.49 and a beta of -1.00. The company has a debt-to-equity ratio of 0.56, a current ratio of 4.01 and a quick ratio of 3.77. Madrigal Pharmaceuticals, Inc. has a 12 month low of $265.00 and a 12 month high of $615.00.

Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) last posted its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($2.57) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.04 by ($2.61). The business had revenue of $321.08 million for the quarter, compared to analyst estimates of $310.36 million. Madrigal Pharmaceuticals had a negative return on equity of 43.76% and a negative net margin of 30.08%.The firm's revenue for the quarter was up 210.8% compared to the same quarter last year. During the same period last year, the company posted ($2.71) EPS. As a group, research analysts forecast that Madrigal Pharmaceuticals, Inc. will post -23.47 earnings per share for the current year.

Insider Buying and Selling

In other Madrigal Pharmaceuticals news, General Counsel Shannon T. Kelley sold 360 shares of the firm's stock in a transaction dated Friday, March 6th. The stock was sold at an average price of $431.94, for a total value of $155,498.40. Following the transaction, the general counsel directly owned 12,138 shares of the company's stock, valued at $5,242,887.72. This trade represents a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Mardi Dier sold 1,982 shares of the business's stock in a transaction dated Friday, March 6th. The stock was sold at an average price of $430.87, for a total value of $853,984.34. Following the transaction, the chief financial officer owned 12,490 shares in the company, valued at approximately $5,381,566.30. This represents a 13.70% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 55,612 shares of company stock valued at $28,326,065. 21.50% of the stock is owned by corporate insiders.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company's pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders.

The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-β agonist in Phase 3 development for the treatment of NASH.

Want to see what other hedge funds are holding MDGL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.